Oppenheimer & CO Inc Seagen Inc. Transaction History

Oppenheimer & CO Inc

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 07, 2023	SELL	$191.51 - $216.16 $19,917 - $22,480	-104 Reduced 1.36%	7,536 $1.6 Million
Q2 2023 Aug 02, 2023	SELL	$187.64 - $206.25 $46,159 - $50,737	-246 Reduced 3.12%	7,640 $1.47 Million
Q1 2023 May 10, 2023	BUY	$127.59 - $203.08 $110,237 - $175,461	864 Added 12.3%	7,886 $1.6 Million
Q4 2022 Feb 07, 2023	SELL	$117.37 - $139.17 $15,610 - $18,509	-133 Reduced 1.86%	7,022 $902,000
Q3 2022 Nov 14, 2022	SELL	$135.27 - $180.11 $52,890 - $70,423	-391 Reduced 5.18%	7,155 $979,000
Q2 2022 Aug 08, 2022	SELL	$108.81 - $179.33 $7,616 - $12,553	-70 Reduced 0.92%	7,546 $1.34 Million
Q1 2022 May 12, 2022	SELL	$119.61 - $157.85 $59,805 - $78,925	-500 Reduced 6.16%	7,616 $1.1 Million
Q4 2021 Feb 02, 2022	SELL	$142.57 - $190.86 $5,417 - $7,252	-38 Reduced 0.47%	8,116 $1.26 Million
Q3 2021 Nov 12, 2021	BUY	$142.45 - $169.82 $14,957 - $17,831	105 Added 1.3%	8,154 $1.39 Million
Q2 2021 Aug 03, 2021	SELL	$135.08 - $161.1 $22,288 - $26,581	-165 Reduced 2.01%	8,049 $1.27 Million
Q1 2021 May 10, 2021	SELL	$137.51 - $190.8 $122,383 - $169,812	-890 Reduced 9.78%	8,214 $1.14 Million
Q4 2020 Feb 11, 2021	BUY	$164.63 - $211.93 $1.5 Million - $1.93 Million	9,104 New	9,104 $1.59 Million

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Oppenheimer & CO Inc, based on Form 13F filings with the SEC.

Stay updated on Oppenheimer & CO Inc with notifications on news.